Biohaven (NYSE:BHVN) Stock Rating Lowered by Wall Street Zen

Biohaven (NYSE:BHVN) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.

Several other equities research analysts have also weighed in on BHVN. Morgan Stanley increased their target price on Biohaven from $19.00 to $21.00 and gave the stock an “overweight” rating in a research report on Tuesday. Weiss Ratings raised Biohaven from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. TD Cowen reissued a “buy” rating on shares of Biohaven in a report on Wednesday, August 26th. HC Wainwright reiterated a “neutral” rating and issued a $10.00 price target on shares of Biohaven in a report on Thursday, September 10th. Finally, Citigroup reaffirmed a “buy” rating on shares of Biohaven in a research report on Friday, September 18th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $20.80.

Biohaven Stock Up 3.8%

BHVN opened at $14.42 on Friday. Biohaven has a 1-year low of $7.48 and a 1-year high of $18.24. The company has a current ratio of 3.05, a quick ratio of 3.05 and a debt-to-equity ratio of 21.23. The business has a 50 day moving average of $13.61 and a 200-day moving average of $12.31. The stock has a market capitalization of $2.18 billion, a price-to-earnings ratio of -3.74 and a beta of 1.36.

Biohaven (NYSE:BHVN) last announced its earnings results on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.15). As a group, sell-side analysts anticipate that Biohaven will post -3.05 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC boosted its holdings in shares of Biohaven by 1,145.9% during the first quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company’s stock valued at $148,214,000 after acquiring an additional 16,127,247 shares during the period. BlackRock Inc. acquired a new position in Biohaven in the 2nd quarter valued at $196,574,000. Jupiter Topco LLC acquired a new stake in Biohaven during the 2nd quarter worth about $127,852,000. Stempoint Capital LP purchased a new stake in shares of Biohaven during the 1st quarter worth approximately $13,489,000. Finally, Bank of America Corp DE bought a new position in shares of Biohaven during the 2nd quarter valued at $21,990,000. 88.78% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Biohaven

Here are the key news stories impacting Biohaven this week:

• Positive Sentiment: Biohaven says a pivotal Phase 3 trial of BHV-1300 for Graves’ disease is underway and presented three research posters at the American Thyroid Association meeting. The program could address a disease with few recent treatment advances, though trial progress is not a guarantee of success. Biohaven Graves’ disease Phase 3 and ATA announcement
• Positive Sentiment: HC Wainwright raised several future EPS estimates, including narrowing its projected losses for 2026–2029 and forecasting positive EPS in 2030. These revisions may bolster expectations for longer-term financial improvement.
• Positive Sentiment: A separate report says a Morgan Stanley analyst expects BHVN shares to rise, adding a favorable analyst signal; the article headline does not provide the rationale or target. Morgan Stanley analyst outlook
• Negative Sentiment: Despite its improved forecasts, HC Wainwright maintained a Neutral rating and a $10 price target, below the recent share price—suggesting that the analyst sees downside relative to current levels.

Biohaven Company Profile

Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and neuropsychiatric diseases, as well as certain immunological and rare disorders. The company’s research activities include small-molecule medicines, monoclonal antibodies and other innovative therapeutic approaches.

Biohaven’s pipeline has included investigational treatments for conditions such as migraine, obsessive-compulsive disorder, spinal muscular atrophy, amyotrophic lateral sclerosis, mood disorders and autoimmune diseases.